Amgen Inc. $AMGN Shares Bought by Talbot Financial LLC

Talbot Financial LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,875 shares of the medical research company’s stock after acquiring an additional 1,452 shares during the period. Amgen accounts for 1.9% of Talbot Financial LLC’s investment portfolio, making the stock its 17th largest holding. Talbot Financial LLC’s holdings in Amgen were worth $26,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rational Advisors Inc. raised its holdings in Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after purchasing an additional 24 shares in the last quarter. Beacon Financial Advisory LLC boosted its holdings in Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after purchasing an additional 25 shares in the last quarter. James T. Borello RIA boosted its holdings in Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after purchasing an additional 25 shares in the last quarter. Sweeney & Michel LLC increased its position in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after purchasing an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. increased its position in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $4.56 during trading on Monday, hitting $427.93. 937,316 shares of the stock were exchanged, compared to its average volume of 2,748,843. The company has a fifty day moving average price of $415.54 and a two-hundred day moving average price of $374.94. The company has a market cap of $231.35 billion, a PE ratio of 26.58, a P/E/G ratio of 3.17 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio is 62.65%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed Amgen’s cancer treatment IMDELLTRA, a regulatory and commercial milestone that could improve the drug’s access and revenue prospects in the Australian market. PBAC conditionally backs IMDELLTRA
• Positive Sentiment: Exchange-traded funds purchased approximately $19.4 million of Amgen shares on October 15, signaling institutional demand and potentially providing technical support for the stock. ETFs Bought $19.4 Million of Amgen
• Positive Sentiment: Wall Street Zen upgraded its rating on Amgen, adding to the favorable analyst commentary surrounding the company. Amgen stock rating upgraded
• Neutral Sentiment: Amgen continues to attract elevated investor attention, although the report primarily reviews existing facts and factors affecting the company rather than introducing a new fundamental catalyst. Amgen attracting investor attention
• Neutral Sentiment: Analyst coverage highlights Amgen among healthcare companies but does not identify a specific new earnings estimate, target-price change or business announcement. Analysts offer insights on Amgen
• Negative Sentiment: Investors are questioning Amgen’s growth outlook. While its established medicines generate substantial cash and its newer treatments offer promise, the company must demonstrate accelerating growth to support a premium valuation after a strong run toward its 12-month high. Amgen has the drugs and the dividend, now it needs growth

Insiders Place Their Bets

In other news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. TD Cowen increased their target price on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Wells Fargo & Company decreased their price target on Amgen from $435.00 to $430.00 and set an “equal weight” rating on the stock in a research note on Monday, October 12th. UBS Group upped their price objective on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a report on Friday, October 9th. Canaccord Genuity Group upped their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Sunday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $387.93.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.